Open AccessCurrent Statin Usage for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Multicenter Survey in Korea
Author(s) -
Kim MiJeong,
Jeon Doo Soo,
Gwon HyeonCheol,
Kim SooJoong,
Chang Kiyuk,
Kim HyoSoo,
Tahk SeungJea
Publication year - 2012
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22038
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , acute coronary syndrome , rosuvastatin , statin , myocardial infarction , atorvastatin , cardiology , odds ratio , confidence interval , hazard ratio
Background: Although high‐dose statin therapy has been reported to improve outcomes in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), patterns of statin usage for such patients have not been reported in real‐world clinical practice. Hypothesis: Some clinical factors would affect the pattern of statin usage in patients with ACS. Methods: In the multicenter prospective registry, 3362 patients with ACS who underwent PCI were analyzed. High‐dose statin treatment was defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg per day. The patterns of statin usage were investigated for 30 days after the index PCI. Results: High‐dose statins were administered prior to PCI to 13.7% and 19.6% of patients with unstable angina/non–ST‐elevated myocardial infarction (UA/NSTEMI) and ST‐elevated myocardial infarction (STEMI), respectively ( P < 0.001). After PCI, 476 (14.2%) patients were maintained on high‐dose statins, and 550 (16.4%) patients received no statins. Independent factors associated with high‐dose statin usage after PCI were STEMI (odds ratio [OR]: 1.704, 95% confidence interval [CI]: 1.321–2.197, P < 0.001), high total cholesterol level (OR: 1.445, 95% CI: 1.136–1.837, P = 0.003), and current smoker (OR: 1.556, 95% CI: 1.206–2.008, P < 0.011). The absence of hypercholesterolemia was an independent factor determining the nonuse of statins (OR: 0.229, 95% CI: 0.148–0.353, P < 0.001). Conclusions: In real‐world clinical practice, high‐dose statin treatment is being underused despite extensive evidence for patients with ACS undergoing PCI, particularly in UA/NSTEMI. Efforts are needed to ensure that clinical practice complies with evidence‐based guidelines. Clin. Cardiol. 2012 doi: 10.1002/clc.22038 This work was supported financially by Pfizer Pharmaceuticals Korea Ltd., which had no role in the study design, data collection, analysis, manuscript writing, or decision to proceed with publication. The authors have no other funding, financial relationships, or conflicts of interest to disclose.